- Profusa, Inc. (PFSA) expects to launch its Lumee tissue oxygen monitoring in the EU in **2Q 2026**, followed by U.S. entry in **1Q 2027**.  **[1859807_0001213900-25-103772_ea026309101ex99-1_profusa.htm:1]** **[1859807_0001213900-25-103772_ea026309101ex99-1_profusa.htm:2]** **[1859807_0001213900-25-103772_ea026309101ex99-2_profusa.htm:3]** **[1859807_0001213900-25-103772_ea026309101ex99-2_profusa.htm:4]** 
- The company projects potential revenue of **$0.5 to $2 million** in **2026**, increasing to **$9 to $13 million** in **2027**, and targeting **$200 to $250 million** by **2030**.  **[1859807_0001213900-25-103772_ea026309101ex99-1_profusa.htm:1]** **[1859807_0001213900-25-103772_ea026309101ex99-1_profusa.htm:2]** **[1859807_0001213900-25-103772_ea026309101ex99-2_profusa.htm:3]** **[1859807_0001213900-25-103772_ea026309101ex99-2_profusa.htm:7]**  
- Profusa's Lumee platform targets a **$10.5 billion+ global addressable market** for tissue oxygen monitoring and aims to reach **over 500 million people** with its continuous glucose monitoring technology.  **[1859807_0001213900-25-103772_ea026309101ex99-1_profusa.htm:1]** **[1859807_0001213900-25-103772_ea026309101ex99-2_profusa.htm:3]** **[1859807_0001213900-25-103772_ea026309101ex99-2_profusa.htm:6]**  
- Development has been supported by over **$100 million** in investment, including a **$22 million PIPE** and a **$100 million Equity Line of Credit**.  **[1859807_0001213900-25-103772_ea026309101ex99-1_profusa.htm:1]** **[1859807_0001213900-25-103772_ea026309101ex99-2_profusa.htm:3]**

Profusa, Inc. outlines path to revenue generation and provides financial projections

- Profusa, Inc. released an updated investor presentation on **October 20, 2025**, highlighting its strategy for "Pioneering real time biochemistry that drives AI - led, personalized healthcare technologies".  **[1859807_0001213900-25-100443_ea026183601ex99-1_profusa.htm:0]** **[1859807_0001213900-25-100443_ea0261836-8k_profusa.htm:1]** 
- The company projects revenue from its Oxygen Platform to be between **$0.5 million and $2 million in 2026**, with total revenue from its Oxygen and Glucose platforms expected to reach **$200 million to $250 million by 2030**.  **[1859807_0001213900-25-100443_ea026183601ex99-1_profusa.htm:3]** **[1859807_0001213900-25-100443_ea026183601ex99-1_profusa.htm:7]**  
- Profusa anticipates launching its Lumee tissue oxygen monitoring in Europe in **1Q2026E** and in the US in **1H2027E**, with revenue from glucose monitoring projected to commence in **2027**.  **[1859807_0001213900-25-100443_ea026183601ex99-1_profusa.htm:3]**  
- Financially, Profusa has secured a **$22 million PIPE** and has access to a **$100 million Equity Line of Credit**, with **$14.0 million** in total cash availability as of October 20, 2025.  **[1859807_0001213900-25-100443_ea026183601ex99-1_profusa.htm:3]** **[1859807_0001213900-25-100443_ea026183601ex99-1_profusa.htm:7]**

Profusa, Inc. Updates Investor Presentation with Revenue Projections and Product Launch Timelines

- Profusa, Inc. announced on **October 7, 2025**, an **additional $1 million investment** in digital treasury assets, bringing its total to **$2 million** as part of its strategy to hedge against macroeconomic uncertainties.  **[1859807_0001213900-25-097141_ea026061101ex99-1_profusa.htm:0]** **[1859807_0001213900-25-097141_ea0260611-8k_profusa.htm:4]** 
- This investment is linked to a financing arrangement with Ascent Partners Fund LLC, involving senior secured convertible promissory notes.  **[1859807_0001213900-25-097141_ea0260611-8k_profusa.htm:1]** 
- The **Second Tranche** of this financing, with a purchase price of **$2,000,000**, closed on **September 30, 2025**.  **[1859807_0001213900-25-097141_ea0260611-8k_profusa.htm:1]** 
- An Account Control Agreement, effective **September 29, 2025**, was established with Ascent, BitGo Prime LLC, and BitGo Trust Company, Inc. to govern the custody of Profusa's **Bitcoin reserve**, which is pledged as collateral for the financing.  **[1859807_0001213900-25-097141_ea026061101ex10-1_profusa.htm:0]** **[1859807_0001213900-25-097141_ea0260611-8k_profusa.htm:1]** 
- Profusa is responsible for a collateral management fee of **3 basis points** of the U.S. monthly digital assets held in the custodial account, payable to BitGo Prime LLC.  **[1859807_0001213900-25-097141_ea0260611-8k_profusa.htm:2]**

Profusa Invests Additional $1 Million in Digital Treasury Assets and Details Collateral Agreement

- Profusa, Inc. entered into Amendment No. 1 to its Securities Purchase Agreement and Senior Secured Convertible Promissory Note on **August 25, 2025**, restructuring its financing and modifying conversion terms.  **[1859807_0001213900-25-080457_ea025456401ex10-1_profusa.htm:0]** **[1859807_0001213900-25-080457_ea025456401ex10-2_profusa.htm:0]** **[1859807_0001213900-25-080457_ea0254564-8k_profusa.htm:1]** 
- The amendment to the Securities Purchase Agreement now provides for **four tranches** of Notes, with the **First Tranche** of **$10,000,000** in aggregate principal amount already closed on **July 11, 2025**.  **[1859807_0001213900-25-080457_ea0254564-8k_profusa.htm:1]** 
- Subsequent tranches include a **Second Tranche** of **$2,222,222** (purchase price **$2,000,000**), a **Third Tranche** of **$5,555,556** (purchase price **$5,000,000**), and a **Fourth Tranche** of **$4,444,444** (purchase price **$4,000,000**), each subject to specific conditions.  **[1859807_0001213900-25-080457_ea0254564-8k_profusa.htm:1]** **[1859807_0001213900-25-080457_ea025456401ex10-1_profusa.htm:1]** 
- The amendment to the Senior Secured Convertible Promissory Note establishes a **Conversion Price** that is the lower of a specified amount or **95% of the lowest VWAP** over the preceding ten trading days, with a **Floor Price** set at **20% of the Closing Sale Price** on **August 22, 2025**.  **[1859807_0001213900-25-080457_ea025456401ex10-2_profusa.htm:0]** **[1859807_0001213900-25-080457_ea0254564-8k_profusa.htm:2]** **[1859807_0001213900-25-080457_ea025456401ex10-3_profusa.htm:4]**

Profusa (PFSA)